Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Comment by chrispion Feb 17, 2021 11:18am
128 Views
Post# 32584514

RE:We're still...

RE:We're still...
working through the new shares that were issued on December 23rd as a result of the warrant conversion (see house # 2 RBC).

Hi barsax,
that would make logical sense but as I stated in a previous post 
https://stockhouse.com/companies/bullboard?symbol=v.bti&postid=32491216 it simply is not true that these shares being sold from RBC are from the warrant holders. The last two financings went into just a few hands. These are well-financed, strong hands and long-time supporters of the company and have no intention of flipping them for pennies. They’ve done their due diligence and realize the tremendous opportunity and $ upside. We have a market cap of $35m CDN. Regardless of what happened in the past, we are in the sweet spot for Bioasis RIGHT NOW … THIS YEAR. Lots and lots of upside here when you look at the HUGE markets in the disease indications they are pursuing.


<< Previous
Bullboard Posts
Next >>